Mark Goldberger MD MPH infectious disease expert has joined the NDA Advisory Board.
Mark brings with him a wealth of experience in and in-depth knowledge of infectious diseases and antimicrobial products as well as extensive FDA expertise, according to the press release. He has insight in these fields, working at the FDA as an expert within the Center for Drug Evaluation and Research (CDER), for which he held various roles of increasing responsibility, including five years as the Director of the Office of Antimicrobial Products. He also spent one year in the Center for Biologics Evaluation and Research (CBER) as Medical Director for Emerging and Pandemic Threat Preparedness.
Following his time at the FDA, Mark joined Abbott as Divisional Vice President involved in multiple areas of both product and policy development, before becoming VP Regulatory Affairs and Senior Advisor following the AbbVie split, providing both regulatory and scientific input into multiple development programs.
Mark is board certified in internal medicine and infectious disease and is a fellow of the Infectious Diseases Society of America.
He is joining an increasing number of former FDA thought leaders at NDA, who since announcing its expansion into the US in 2016, has grown a team of more than 30 regulatory, drug development and scientific communications specialists in their locations in Boston, Princeton and San Francisco.